H J G Abrahams1, M F M Gielissen2, I C Schmits3, C A H H V M Verhagen4, M M Rovers5, H Knoop6. 1. Expert Center for Chronic Fatigue, Radboud University Medical Center, Nijmegen harriet.abrahams@radboudumc.nl. 2. Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam. 3. Expert Center for Chronic Fatigue, Radboud University Medical Center, Nijmegen. 4. Department of Medical Oncology. 5. Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Expert Center for Chronic Fatigue, Radboud University Medical Center, Nijmegen Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam.
Abstract
BACKGROUND: This meta-analysis aimed to (i) examine demographic, disease-related, and treatment-related risk factors, (ii) estimate the prevalence, and (iii) describe the course of severe fatigue following breast cancer (BC) treatment. METHODS: PubMed, PsycINFO, Cochrane, CINAHL, and Web of Science were systematically searched from inception up to 23 November 2015. Risk factors and prevalence rates were analyzed with inverse variance random-effects analyses. Heterogeneity was studied with sensitivity analyses. RESULTS: Twenty-seven studies were included (N = 12 327). Breast cancer survivors (BCS) with a partner were at lower risk for severe fatigue than survivors without a partner [risk ratio (RR) 0.96, 95% confidence interval (CI) 0.93-0.98]. Survivors with stage II or III cancer, and survivors treated with chemotherapy were at higher risk for severe fatigue than survivors with stage 0 or I cancer and without chemotherapy (RR respectively 1.18, 95% CI 1.08-1.28; 1.12, 95% CI 1.06-1.19). Survivors treated with surgery, radiotherapy, and chemotherapy, and survivors with this combination plus hormone therapy were at higher risk than survivors with other treatment combinations (RR respectively 1.18, 95% CI 1.05-1.33; 1.38, 95% CI 1.15-1.66). Survivors treated with surgery and surgery plus radiotherapy were at lower risk than survivors with additional treatments (RR respectively 0.83, 95% CI 0.70-0.98; 0.87, 95% CI 0.78-0.96). Hormone and targeted therapy were no significant risk factors. The pooled prevalence of severe fatigue was 26.9% (95% CI 23.2-31.0), but this should be interpreted with caution because of high heterogeneity. A relatively large decrease in the prevalence of severe fatigue seemed to occur in the first half year after treatment completion. CONCLUSIONS: Approximately one in four BCS suffer from severe fatigue. Risk factors of severe fatigue were higher disease stages, chemotherapy and receiving the combination of surgery, radiotherapy, and chemotherapy, both with and without hormone therapy. Having a partner, receiving only surgery, and surgery plus radiotherapy decreased the risk.
BACKGROUND: This meta-analysis aimed to (i) examine demographic, disease-related, and treatment-related risk factors, (ii) estimate the prevalence, and (iii) describe the course of severe fatigue following breast cancer (BC) treatment. METHODS: PubMed, PsycINFO, Cochrane, CINAHL, and Web of Science were systematically searched from inception up to 23 November 2015. Risk factors and prevalence rates were analyzed with inverse variance random-effects analyses. Heterogeneity was studied with sensitivity analyses. RESULTS: Twenty-seven studies were included (N = 12 327). Breast cancer survivors (BCS) with a partner were at lower risk for severe fatigue than survivors without a partner [risk ratio (RR) 0.96, 95% confidence interval (CI) 0.93-0.98]. Survivors with stage II or III cancer, and survivors treated with chemotherapy were at higher risk for severe fatigue than survivors with stage 0 or I cancer and without chemotherapy (RR respectively 1.18, 95% CI 1.08-1.28; 1.12, 95% CI 1.06-1.19). Survivors treated with surgery, radiotherapy, and chemotherapy, and survivors with this combination plus hormone therapy were at higher risk than survivors with other treatment combinations (RR respectively 1.18, 95% CI 1.05-1.33; 1.38, 95% CI 1.15-1.66). Survivors treated with surgery and surgery plus radiotherapy were at lower risk than survivors with additional treatments (RR respectively 0.83, 95% CI 0.70-0.98; 0.87, 95% CI 0.78-0.96). Hormone and targeted therapy were no significant risk factors. The pooled prevalence of severe fatigue was 26.9% (95% CI 23.2-31.0), but this should be interpreted with caution because of high heterogeneity. A relatively large decrease in the prevalence of severe fatigue seemed to occur in the first half year after treatment completion. CONCLUSIONS: Approximately one in four BCS suffer from severe fatigue. Risk factors of severe fatigue were higher disease stages, chemotherapy and receiving the combination of surgery, radiotherapy, and chemotherapy, both with and without hormone therapy. Having a partner, receiving only surgery, and surgery plus radiotherapy decreased the risk.
Authors: Lidewij D Van Gessel; Harriët J G Abrahams; Hetty Prinsen; Gijs Bleijenberg; Marianne Heins; Jos Twisk; Hanneke W M Van Laarhoven; Stans C A H H V M Verhagen; Marieke F M Gielissen; Hans Knoop Journal: J Cancer Surviv Date: 2018-04-12 Impact factor: 4.442
Authors: Joseph M Gullett; Ronald A Cohen; Gee Su Yang; Victoria S Menzies; Robert A Fieo; Debra L Kelly; Angela R Starkweather; Colleen K Jackson-Cook; Debra E Lyon Journal: Psychooncology Date: 2019-03-14 Impact factor: 3.894
Authors: Heather S L Jim; Aasha I Hoogland; Naomi C Brownstein; Anna Barata; Adam P Dicker; Hans Knoop; Brian D Gonzalez; Randa Perkins; Dana Rollison; Scott M Gilbert; Ronica Nanda; Anders Berglund; Ross Mitchell; Peter A S Johnstone Journal: CA Cancer J Clin Date: 2020-04-20 Impact factor: 508.702
Authors: Alejandro Álvarez-Bustos; Cristina G de Pedro; María Romero-Elías; Javier Ramos; Pablo Osorio; Blanca Cantos; Constanza Maximiano; Miriam Méndez; Carmen Fiuza-Luces; Marta Méndez-Otero; Silvia Martín; Héctor Cebolla; Ana Ruiz-Casado Journal: Support Care Cancer Date: 2021-04-28 Impact factor: 3.603
Authors: Heather S L Jim; Aasha I Hoogland; Hyo Sook Han; Eva Culakova; Charles Heckler; Michelle Janelsins; Geoffrey C Williams; Julienne Bower; Stephen Cole; Zeruesenay Desta; Margarita Bobonis Babilonia; Gary Morrow; Luke Peppone Journal: Contemp Clin Trials Date: 2020-03-05 Impact factor: 2.226
Authors: Nikhil Panda; Ian Solsky; Becky Hawrusik; Gang Liu; Harrison Reeder; Stuart Lipsitz; Eesha V Desai; Kurt W Lowery; Kate Miller; Michele A Gadd; Carrie C Lubitz; Barbara L Smith; Michelle Specht; Jukka-Pekka Onnela; Alex B Haynes Journal: Ann Surg Oncol Date: 2020-08-18 Impact factor: 5.344
Authors: Franziska Holtdirk; Anja Mehnert; Mario Weiss; Johannes Mayer; Björn Meyer; Peter Bröde; Maren Claus; Carsten Watzl Journal: PLoS One Date: 2021-05-07 Impact factor: 3.240
Authors: Adriaan Penson; Sylvia van Deuren; Ewald Bronkhorst; Ellen Keizer; Tom Heskes; Marieke J H Coenen; Judith G M Rosmalen; Wim J E Tissing; Helena J H van der Pal; Andrica C H de Vries; Marry M van den Heuvel-Eibrink; Sebastian Neggers; Birgitta A B Versluys; Marloes Louwerens; Margriet van der Heiden-van der Loo; Saskia M F Pluijm; Martha Grootenhuis; Nicole Blijlevens; Leontien C M Kremer; Eline van Dulmen-den Broeder; Hans Knoop; Jacqueline Loonen Journal: BMC Med Res Methodol Date: 2021-05-16 Impact factor: 4.615